Fredun Pharmaceuticals Ltd(FREDUN)

NSE: FREDUNBSE: 539730

₹ 1,368.1-1.66%refreshed 23 Oct, 03:50 pm ISTMarket cap: ₹ 2,263 crWebsite: www.fredungroup.comUpdated: 24 Oct 2026

About

Fredun Pharmaceuticals Ltd is an India-based diversified healthcare company operating across generic pharmaceuticals, nutraceuticals, mobility products, animal healthcare, and pet wellness services, with shares listed on the Bombay Stock Exchange. In FY26 the company reported revenue of ₹633.33 crores, expanding from ₹453.8 crores in FY25. Its manufacturing base is anchored at a WHO GMP-approved facility in Palghar, and it exports to customers across 52 countries including Africa, South East Asia, CIS countries, and Latin America.^[1][2][3][4]

Business segments

The vintage business - allopathic formulations, exports, and OEM/loan-licensing - generated approximately ₹350 crores annually as of Q1 FY26 and is targeted to grow at 15 - 18% per year over the next 7 - 9 years.^[5]
New-age verticals - pet care (Freossi), Fredun Nutrition, Fredun Mobility, and wellness - contributed approximately ₹100 - 110 crores in FY25 and are targeted to grow at 35 - 40% CAGR.^[5]
FY25 revenue mix was 83% domestic and 17% export; by Q1 FY26 export share had risen to 25 - 27% of sales.^[2][5]

Products and brands

Fredun operates across generic pharmaceuticals, animal healthcare, nutraceuticals, cosmeceuticals, longevity solutions, mobility products, and specialty therapeutics, including a Hormone Range Products line for advanced performance and preventive health.^[3]
Freossi is the pet care brand, covering functional food, grooming, and wellness; it has expanded into large animals with Freossi Tone+ (lactation support) and Freossi Power (joint health) for cows, buffaloes, horses, and cattle.^[2]
Fredun Gx is a branded generic line targeting Tier 2/3/4 markets; it generated ₹55 - 60 crores in FY25 with a target of ₹85 crores in FY26.^[5]
Fredun Mobility has 143 SKUs and includes Chuu Balm; the Mobilitex division targeting physiotherapists was launched in Q2 FY26.^[2][4]
Animal healthcare products range from allopathic formulations to on-field diagnostic kits; the company also manufactures dietary and herbal supplements, nutraceuticals, and personal hygiene products.^[3]

Manufacturing and operations

The primary manufacturing facility is at Palghar, Maharashtra, and holds WHO GMP approval; it is undergoing expansion aimed at making it one of India's largest single-location pharma plants within two years of November 2025.^[3][4]
FY25 capacity additions at Palghar included an automatic tube filling machine from Italy (doubling daily filling capacity), 3,000 kg/day of additional ointment manufacturing capacity, and a 7th granulation suite adding 2 tonnes/day of granulation.^[2]
Fredna Vet Diagnostics operates India's first 24×7 dedicated veterinary diagnostic centre, equipped with a CBCT machine imported from Finland and advanced ultrasound, with a pet ambulance service.^[2]

Key operating numbers

697 products registered globally as of FY25/Q2 FY26, with 1,200+ products under registration globally as of Q2 FY26.^[2][4]
Order book stood at over ₹200 crores as of Q1 FY26, providing approximately two quarters of revenue visibility.^[5]
EBITDA margin was 12.1% in FY25 (vs 11.1% in FY24), 14.18% in Q1 FY26, and 15.37% in Q2 FY26.^[2][5][4]
Debtor days were 143 in FY25; trade receivables rose to ₹177.1 crores in FY25 from ₹64.8 crores in FY24, and operating cash flow was negative ₹29.06 crores in FY25 before turning positive in H1 FY26.^[2][4]

Customers and distribution

Export customers span Africa, South East Asia, CIS countries, and Latin America, alongside leading pharma companies in India, across 52 countries in total.^[3][4]
Institutional domestic sales include contracts with Indian Railways, the Defence sector, and TNMAC, diversifying beyond private pharma clients.^[2]
Fredun Mobility is present across Pan Maharashtra and expanding into Gujarat and Rajasthan; Chuu Balm is available in MMRDA and parts of Gujarat.^[2]

Expansion and capex

Palghar facility expansion has commenced; management targets being among India's largest single-location pharma plants within two years of Q2 FY26.^[4]
Wagr.ai (GPS, health monitoring, vet consultation; 140,000 pet parents) was acquired at zero upfront cost with planned capex of ₹4 - 5 crores over 18 - 24 months followed by a further ₹5 - 7 crores.^[4]
A second Fredna Vet Diagnostics centre is planned in north Mumbai by end of FY26, followed by expansion to Ahmedabad, Pune, Chennai, Bangalore, Hyderabad, and Delhi.^[5][2]
Fredun Mobility plans to expand its SKU range from 143 to 210, with approximately 30 new products under development including Sports and Critical Care categories.^[2]

Recent developments

On 22 September 2026, Fredun acquired a 26% stake in Goodman Vetcare Pvt. Ltd., which had FY26 revenue of ₹23.6 crores (vs ₹14.1 crores in FY24) and is targeted to reach approximately ₹40 crores in FY27 and approximately ₹100 crores by FY31.^[6]
One Pet Stop Private Limited - a tech-enabled at-home pet grooming platform serving over 4,000 recurring pet parents - was acquired in Q1 FY26; Wagr Retail was also developed, creating an integrated pet ecosystem spanning diagnostics, nutrition, wellness, retail, and veterinary care.^[4][3]
Snacky Jain - India's first Jain functional pet food under the Freossi brand - was launched in Q2 FY26 with 12 tonnes sold via pre-orders and rolling out across 6 cities through vet clinics, online platforms, and retail.^[4]
Pet care products were launched in Sri Lanka in Q2 FY26; product registrations are underway in the Philippines and GCC markets.^[4]

Market Cap

₹2,263 Cr

High / Low

₹1,666 / 454

Stock P/E

49.4

Price / Book

8.1

Book Value

₹504

EPS

₹19.9

No. of Shares

0.55 Cr

ROCE

21.3%

ROE

15.6%

OPM

13.5%

Debt / Equity

0.80

Sales

₹633 Cr

Net Profit

₹33 Cr

Promoter holding

44.6%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials